ArticleNPJ precision oncology2019

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.

Bhavya Yarlagadda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.